Travere Boosts Cash Position As Investors Brace For Filspari Data (NASDAQ:TVTX)

Treatment of kidney diseases at urology. Urologist palpation woman

peakSTOCK/iStock via Getty Images


Travere Therapeutics (NASDAQ:TVTX), a San Diego-based biopharmaceutical company, specializes in developing and delivering treatments for rare kidney, liver, and metabolic diseases. They recently received FDA accelerated approval for their lead product, sparsentan, targeting specific kidney disorders, and are also

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *